These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4360581)

  • 1. Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Ida S; Hinuma Y; Chu CT; Chiou JF; Lai JG
    Gan; 1973 Dec; 64(6):545-53. PubMed ID: 4360581
    [No Abstract]   [Full Text] [Related]  

  • 2. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
    [No Abstract]   [Full Text] [Related]  

  • 3. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 4. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
    Kottaridis SD; Goula I; Kiparissiadis P
    Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamics of Epstein--Barr virus antibody titre in nasopharyngeal carcinoma.
    Lynn TC; Tu SM
    Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):201-5. PubMed ID: 228893
    [No Abstract]   [Full Text] [Related]  

  • 6. Epstein-Barr virus serology in the control of nasopharyngeal carcinoma.
    Levine PH; Connelly RR; Milman G; Easton J
    Cancer Detect Prev; 1988; 12(1-6):357-62. PubMed ID: 2846170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of antibodies to Epstein-Barr virus DNase and viral capsid antigen for prognostication of patients with nasopharyngeal carcinoma.
    Hsu MM; Chen JY; Chen CJ
    Taiwan Yi Xue Hui Za Zhi; 1988 Oct; 87(10):984-8. PubMed ID: 2853721
    [No Abstract]   [Full Text] [Related]  

  • 8. Cell-mediated immunity to Epstein-Barr virus in nasopharyngeal carcinoma.
    Cahn SH; Chew TS; Kunaratnam N
    Lancet; 1979 Apr; 1(8121):884-5. PubMed ID: 86139
    [No Abstract]   [Full Text] [Related]  

  • 9. The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen.
    Ng MH; Ho HC; Kwan HC
    IARC Sci Publ (1971); 1978; (20):449-58. PubMed ID: 215527
    [No Abstract]   [Full Text] [Related]  

  • 10. Epstein-Barr Virus antibodies in patients with carcinoma of the nasopharynx and carcinoma of other sites in the head and neck.
    Sako K; Minowada J; Marchetta FC
    Am J Surg; 1975 Oct; 130(4):437-9. PubMed ID: 170838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus--discovery, properties and relationship to nasopharyngeal carcinoma.
    Epstein MA
    IARC Sci Publ (1971); 1978; (20):333-45. PubMed ID: 215517
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma in Northern Ireland.
    Coyle PV; Wyatt D; Connolly JH; Lynch GA
    Ir J Med Sci; 1987 Jun; 156(6):182-4. PubMed ID: 3040619
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro transfer of cellular immunity against nasopharyngeal carcinoma using transfer factor from donors with Epstein-Barr virus antibody activity.
    Brandes LJ; Goldenberg GJ
    Cancer Res; 1974 Nov; 34(11):3095-101. PubMed ID: 4371172
    [No Abstract]   [Full Text] [Related]  

  • 14. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
    Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
    Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Epstein Barr virus antibody in nasopharyngeal carcinoma.
    Hsu MM; Chiou JF; McCabe BF
    Ann Otol Rhinol Laryngol; 1974; 83(1):19-25. PubMed ID: 4359674
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: Epstein-Barr virus and carcinoma.
    Rossouw E; Bey E; Joosting AC; Gear JH
    S Afr Med J; 1976 Mar; 50(14):529. PubMed ID: 179156
    [No Abstract]   [Full Text] [Related]  

  • 17. Epstein-Barr virus infections.
    Middleton PJ
    Can Med Assoc J; 1974 Jan; 110(1):9-10. PubMed ID: 4358535
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma].
    Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P
    Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.
    Chatani M; Teshima T; Inoue T; Yoshino K; Ikegami N; Hirai K; Shimakage M
    Laryngoscope; 1991 Jun; 101(6 Pt 1):626-9. PubMed ID: 1645832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.